Jonathan Beer

Jonathan Beer

Company: Novartis

Job title: Director of Disruptive Technologies


16.20 | 13.20 – Chair’s Closing Remarks: What’s Next For Liquid Biopsy in Precision Oncology 4:20 pm

What new opportunities are there for liquid biopsies to further precision therapy approaches in oncology What does clinical evidence show us in terms of liquid biopsy replacing the ‘gold standard’ become a reality in some instances – (Drawing on case study examples) Reflecting on the core challenges industry needs to solveRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.